Vision Statement: The Neuro IGNITE Center refines outcome measures, biomarkers and clinical trial design to optimize accurate and efficient investigation of novel therapeutic methods for neurologic and neuromuscular disorders.

Mission Statement: The Neuro IGNITE Center will promote, facilitate and support accelerated development and utilization of novel therapeutics for neurogenetic disorders: increase clinical trial operation and administration efficiency; improving the accuracy and reliability of outcome measures used for neurological disorders by collaborating with trialists, bioengineers and biomedical scientists; optimize clinical trial design, data collection and data analysis by collaborating with statisticians and bioinformatics specialists and integrating novel outcome measures and surrogate endpoints that accurately characterize treatment of genetic neurological disorders; efficiently integrate collection of post-approval real-world data to monitor treatment effects and determine new unmet needs.

Translational Science

From the Bench to the Bedside: Our Integrated Approach

The Neuro IGNITE Center transforms basic and translational discoveries into tangible patient benefits. Our integrated cores work in synergy to push the boundaries of what is possible in neurogenetic treatment.

Biomarker Discovery: We are at the forefront of identifying and validating biomarkers that provide a deeper understanding of disease. We utilize machine learning and artificial intelligence to define novel biomarkers from a multimodal approach that integrates circulating, imaging, and functional digital health outcomes. Our comprehensive view of disease progression and therapeutic response is created by integrating clinical data with insights from blood and CSF proteomic and other circulating biomarkers, muscle biopsies, autopsies and other patient-derived specimens, and advanced PET, MRI and ultrasound imaging. The center’s repository of clinically characterized specimens is an essential resource for both basic and translational investigations.

Outcomes & Innovation: Our work focuses on refining how we measure what matters to patients. We do this by developing and adapting novel outcome measures, including digital and patient-reported outcomes.Collaborating with experts like bioengineers, we integrate wearables and other digital tools into clinical trials to provide a more precise and comprehensive picture of a patient’s health. This approach allows us to accurately monitor structural and functional characteristics, improving the sensitivity for detecting important changes in different neuromuscular diseases. By defining the Minimal Clinically Important Difference (MCID), we ensure that statistical improvements truly translate into meaningful clinical benefits for patients.

Trial Design & Readiness: Our expertise lies in designing trials for rare and ultra-rare disorders.We develop tailored trial designs and utilize novel methods of data acquisition and analysis to achieve sufficient efficacy even with small, heterogeneous patient populations.

This work is supported by a robust operational infrastructure at the Neuro IGNITE Center, which serves as a platform for quickly translating research into diverse patient populations, including first-in-human studies Our data management team’s close collaboration with biostatisticians and bioinformatics specialists streamline data collection, and organization, supporting research and and clinical care programs.

Artificial Intelligence & Machine Learning for Therapeutic Response Evaluation in Neuromuscular Disorders

We develop AI and machine learning solutions to enhance the evaluation of therapeutic response across neuromuscular disorders. Our models integrate multimodal data, including neuroimaging, electrophysiology, molecular profiles, neurocognitive data, and patient-reported outcomes, to quantify treatment effects and inform individualized care. In alignment with genetic interventions, our AI/ML work supports data-driven decision-making in both clinical trials and real-world applications. We are developing scalable foundational models capable of learning from heterogeneous, multisite datasets. These models are designed to capture both shared and disease-specific patterns across neuromuscular conditions, enabling cross-disorder insights and flexible deployment. By combining deep learning with interpretable outputs and clinically meaningful outcome measures, we aim to create practical tools that support therapeutic evaluation and bring advanced analytics closer to everyday clinical and research workflows.

The Neuro IGNITE Center is a hub of active research studies and collaborations that are advancing the field of neuromuscular medicine. Our projects span the entire translational spectrum, from natural history studies to sponsored clinical trials for gene therapies.

Clinical Trials & Studies: We lead and participate in a wide range of studies, including sponsored studies, investigator-initiated studies, and natural history projects. This includes groundbreaking work in antisense oligonucleotide and AAV gene therapy treatments.

Our neuromuscular research team has collaborated in the testing and development of many antisense oligonucleotide (ASO) and small interfering RNA (siRNA) compounds for neuromuscular conditions including spinal muscular atrophy (SMA), myotonic dystrophy (DM), amyotrophic lateral sclerosis (ALS), and facioscapulohumeral muscular dystrophy (FSHD). These ASO and siRNA approaches typically address the root cause of neuromuscular diseases, either by reducing production of unhealthy molecules or increasing production of missing healthy molecules. Our team’s greatest success with ASO treatments to date has been with the clinical trial of nusinersen to treat SMA. We  delivered the first in-human treatment to an infant with SMA in 2013, and assisted in multiple clinical trials of nusinersen which led to the rapid FDA approval in 2016. Now more than 14,000 people with SMA receive nusinersen treatment worldwide, and the Neuro IGNITE center continues to collect real-world data from patients on nusinersen treatment as the disease course changes in response to treatment, and develop and adapt new approaches to address the remaining symptoms of SMA.  Experience with nusinersen established the role of antisense oligonucleotides in treating neurological disorders.  We also played significant roles in validating risdiplam, an orally administered splicing modifier that the FDA approved for SMA, and onasemnogene abeparvovec, the first AAV gene therapy approved by the FDA for systemic infusion.

Real-World Data: We efficiently integrate real-world clinical data to monitor the long-term effects of treatments and identify new unmet needs. This continuous loop of data collection and analysis drives quality improvement and helps us define toxicities, optimal management, and new phenotypes emerging in patients receiving genetic treatments.

A Changing Landscape: The advent of disease-modifying treatments has created a need for precision medicine and novel neuroregenerative methods to address residual deficits. The Neuro IGNITE Center is positioned to develop biomarkers, outcome measures, and trial designs required to validate these complementary treatments to improve the quality of life for all neuromuscular patients, not just those in a single trial.

The Stanford Neuro IGNITE Center is at the forefront of innovation in genetic neurological disorders, fostering collaborations both within Stanford and with external partners to transform clinical trial methodologies and enhance therapeutic development, all while maintaining a strong focus on patient-centered care.

Our dedication to advancing the field of neurogenetic medicine is further strengthened by a diverse array of esteemed collaborators, including:

Stanford Collaborators

Stanford Neurology & Neurological Sciences

The Stanford Neurology & Neurological Sciences Department is a recognized center of excellence in neurology for over four decades. With over 140 faculty members and access to four premier teaching hospitals, the department is committed to advancing patient care through cutting-edge treatments and innovative research.

Stanford Bioengineering

Research at Stanford Bioengineering seeks to measure and understand the world around us with utmost care and precision, to recreate the phenomena we witness, and to design tools and approaches with real applications that impact humanity.

The Human Performance Laboratory

The Human Performance Laboratory is a center for excellence in health science providing a unique link between Stanford’s prestigious Athletics program, the School of Medicine, and various Academic Departments within the University. The center performs interdisciplinary research integrating biomechanics, biomedical engineering, physiology, psychology, and rehabilitation.

Wu Tsai Neuroscience Institute 

The Wu Tsai Neurosciences Institute is dedicated to understanding how the brain gives rise to mental life and behavior, in health and disease.

The Center for Definitive and Curative Medicine

In the Stanford Center for Definitive and Curative Medicine (CDCM), researchers are use cell and gene therapies to treat diseases from common diagnoses such as diabetes to rare diseases of the brain, blood, skin, immune system, and other organs. The CDCM translates exploratory and preclinical studies into definitive cures for currently incurable diseases.

The Cardiovascular Institute

Established in 2004, the Stanford Cardiovascular Institute establishes educational and training programs in cardiovascular medicine and promotes research and clinical applications through awarded seed grants.

The Innovative Medicines Accelerator

The Stanford Innovative Medicines Accelerator (IMA) facilitates the translation of Stanford research discoveries into new medicines while expanding knowledge of human biology.

The Lucas Center for MRI Research

The Richard M. Lucas Center for Imaging houses resources devoted to research in magnetic resonance imaging (MRI), spectroscopy (MRS), and X-Ray/CT imaging supports interdisciplinary research illuminating human physiology and the diagnosis and treatment of human diseases. It advances imaging in healthcare at Stanford through technology creation and development, translational research and education. 

Institute for Stem Cell Biology and Regenerative Medicine

The Stanford Institute for Stem Cell Biology and Regenerative Medicine was established in 2002 to build on Stanford’s leadership in stem cell science and to set the foundations for regenerative medicine.The institute is devoted to exploring stem cell generation, differentiation.and therapeutic potential.

The Brain Organogenesis Program

The Stanford Brain Organogenesis Program brings together expertise in neurosciences, stem cell biology, engineering, chemistry, medicine and law/ethics to non-invasively construct and deconstruct inaccessible stages of human brain development and function in health and brain disorders.

The Center for Cognitive and Neurobiological Imaging

The Stanford Center for Cognitive and Neurobiological Imaging (CNI) is a shared facility, that provides resources for researchers and students in cognitive and neurobiological sciences.

Affiliated Partners

Academic Institutions

• Columbia University

• University of California, Irvine

• University of California, San Diego

• University of Florida

• University of Kansas Medical Center (KUMC)

• University of Miami

• University of Rochester

• Virginia Commonwealth University

Industry Partners

• Annji Pharmaceutical 

• Abcuro, Inc.

• Alcyone Therapeutics

• Alexion Pharmaceuticals

• AMO Pharma

• Arcellx, Inc.

• Argenx, Inc.

• Astellas Pharma

• Atyr Pharma

• Avidity Biosciences

• Biogen, Inc.

• Bristol Meyer Squibb

• Catalyst Pharma

• Cytokinetics, Inc.

• Dyne Therapeutics

• Edgewise Therapeutics

• Expansion Therapeutics

• Glaxo SmithKline

• Insmed Pharmaceuticals

• Ionis Pharmaceuticals

• Jacobus Pharma

• Janssen (now Johnson & Johnson Innovative Medicine)

• Kyverna Therapeutics

• Mallinckrodt

• NMD Pharma

• Novartis Gene Therapies

• Perkin Elmer

• PepGen, Inc.

• Pfizer, Inc.

• PTC Therapeutics

• Regenxbio, Inc.

• RESTEM, LLC

• Roche / Genentech

• Sarepta Therapeutics

• Sanofi Pharmaceuticals

• Satellos Bioscience 

• Scholar Rock, Inc.

• Spur Therapeutics

• Takeda Pharmaceuticals

• Vertex Pharmaceuticals

• Viking Therapeutics

Community, Non-Profit Partners, & Clinical Research Networks

• A Foundation Building Strength for Nemaline Myopathy

• CMT Association 

• Cure SMA

• FSHD-CRN

• Inherited Neuropathies Consortium

• Jain Foundation

• Muscular Dystrophy Association 

• Myotonic Dystrophy Foundation 

• SMA Foundation

• Solve FSHD

• Solve GNE

• The Marigold Foundation 

• The Myotonic Dystrophy Clinical Research Network (DMCRN)

• Wilson-5 Foundation

Government Agencies 

• Department of Defense 

• U.S. Food and Drug Administration (FDA)

• National Institutes of Health (NIH)